QUOTE AND NEWS
TheStreet.com  Jan 2  Comment 
NEW YORK (TheStreet) -- Shares of Achillion Pharmaceuticals  rose 7.52% to $13.17 on Friday after RA Capital portfolio manager Peter Kolchinsky identified the company as an attractive takeover target. Kolchinsky noted Achillion's four...
Benzinga  Dec 29  Comment 
The Manitowoc Company, Inc. (NYSE: MTW) shares jumped 14.15% to $23.88 in pre-market trading on report of Icahn stake. Carl Icahn reported a 7.77% stake in Manitowoc, and called for separation of crane and foodservice segments into separate...
Motley Fool  Dec 28  Comment 
Achillion Pharmaceuticals ACH-3102 helps cure hepatitis C patients more quickly than Gilead Sciences and AbbVie.
Benzinga  Dec 24  Comment 
Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) rose 27.64% to $18.70 after the FDA approved a New Drug Application for Adamas Pharmaceuticals' Namzaric for the treatment of moderate to severe dementia of the Alzheimer's type. Navigator Holdings...
Benzinga  Dec 24  Comment 
Navigator Holdings Ltd. (NYSE: NVGS) shares jumped 6.48% to $19.06 in pre-market trading on positive Jim Cramer/Mad Money comments. Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) shares gained 5.15% to $12.45 in the pre-market trading session...
Motley Fool  Dec 23  Comment 
Achillion Pharmaceuticals reported mixed results from clinical trials that sent shares tumbling.
TheStreet.com  Dec 23  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES Achillion was downgraded at Robert Baird to outperform from neutral. Twelve-month price target is $16. Recent antiviral clinical data fell short of expectations, Robert Baird said. Avon Products was...
Benzinga  Dec 23  Comment 
Analysts at Baird downgraded Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) from Outperform to Neutral. The price target for Achillion Pharmaceuticals has been raised from $12 to $16. Achillion Pharmaceuticals shares have surged 356.93%...
Benzinga  Dec 23  Comment 
TheStreet.com  Dec 22  Comment 
BOSTON (TheStreet) -- Sorry to play the Scrooge in front of Christmas, but the data released Monday on Achillion Pharmaceuticals' hepatitis C "nuc" ACH-3422 falls short of spectacular. Tamp down your hopes and dreams if you were expecting...





You may also be interested in articles related to Achillion Pharmaceuticals (ACHN):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki